Does Kangmei Pharmaceutical (SHSE:600518) Have A Healthy Balance Sheet?

Simply Wall StJul 15 22:39 ET

Announcement of Kangmei Pharmaceuticals' expected half-year performance in 2024.

Sensex a shareJul 12 12:00 ET · Announcements

Kangmei Pharmaceutical (600518.SH): Net income in the first half of the year is expected to increase by 14 million yuan to 21 million yuan year-on-year.

Kangmei Pharmaceutical (600518.SH) announced its performance forecast for the first half of 2024, and according to preliminary calculations by the finance department, the company is expected to achieve a net income attributable to the owner of the mother company of 14 million to 21 million yuan in the first half of 2024, which is a turnaround compared with the same period last year; it is expected to achieve a net income attributable to the owner of the mother company after deducting non-recurring gains and losses of -120 million yuan to -90 million yuan in the first half of 2024. The company is committed to optimizing its management and cost control, and promoting increased production and efficiency in various ways.

Gelonghui FinanceJul 12 05:07 ET

Kangmei Pharmaceutical (stock code: 600518.SH) has revoked other risk warnings on its stocks.

According to the regulations of the Shanghai Stock Exchange listing rules, Kangmei Pharmaceutical (stock code: 600518.SH), the ST listed company, will be suspended for one day on July 3, 2024, and will resume trading on July 4, 2024 with the cancellation of other risk warnings. After the cancellation of other risk warnings, the company's stock will be traded on the exchange rather than on the risk warning board, and the daily limit of stock price fluctuations will be changed from 5% to 10%. The company's stock abbreviation will be changed from "ST Kangmei" to "Kangmei Pharmaceutical", and the stock code will remain as "600518".

Gelonghui FinanceJul 2 06:07 ET

Kangmei Pharmaceutical (600518.SH): The company's stocks apply for the revocation of other risk warnings.

Kangmei Pharmaceutical (600518.SH) announced on June 26 that as of the disclosure date of the announcement, the corresponding situation of the "other risk warnings" triggered by the audit report with a negative opinion on its internal controls in 2020 has been eliminated. The Bohai International Trust Co., Ltd. and Kangmei (Bozhou) Huatuo International Chinese Medicine City Co., Ltd., Bozhou Xincheng World Trading Co., Ltd. and other financial loan contract disputes (referred to as the "Bohai Trust Case") have been adjudicated and entered the implementation process. The company has taken measures to protect its legitimate rights and interests in accordance with the law, and the company's profitability continues to improve.

Gelonghui FinanceJun 26 07:01 ET

Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Stock Most Popular Amongst Retail Investors Who Own 57%, While Private Companies Hold 30%

Simply Wall StJun 24 21:15 ET